Anti-cyclin A and anti-cyclin E antibodies were were obtained from Bioworld Technology (St Louis Park, MN). growth inhibition effect of pemetrexed combined with icotinib on NSCLC cells were schedule-dependent in vitro in vivo. Treatment with pemetrexed followed by icotinib (P-I) had significantly stronger anticancer ability than treatment with icotinib followed by pemetrexed (I-P) and concomitant treatment with pemetrexed and icotinib (P?+?I). Cell cycle analysis revealed that pemetrexed blocked cells in S phase, whereas icotinib arrested cells in G1 phase. We also found that icotinib markedly enhanced the pro-apoptotic activity of pemetrexed via cytochrome-C/Caspase/Bcl-2 signaling pathway. In addition, our results showed that pemetrexed alone increased the levels of p-EGFR, p-AKT and p-MAPK, which were inhibited by icotinib. Finally, we showed that the washout period of icotinib was no less than 96?h. Conclusions Sequential treatment of NSCLC cells with pemetrexed followed by icotinib had powerful antiproliferative effect, and it could become a novel effective combination therapy for NSCLC patients. strong class=”kwd-title” Keywords: Icotinib, Lung cancer, EGFR mutation, Synergy, Washout period Background Primary lung cancer is the most common form of cancer in terms of both incidence and death worldwide [1]. Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer and accounts for about 80% of all lung cancer [2], The overall 5-year survival rate for stage IIIB/IV NSCLC is 1C5%, and approximately 70% of NSCLC patients are diagnosed at an advanced stage with local metastasis [3]. Systemic therapy is the backbone of treatments of advanced NSCLC. First-line platinum-based doublet chemotherapy or teratment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) is optional according to EGFR status [4C9]. However, the benefits of first-line chemotherapy seem to have reached a plateau and only progress free survival (PFS) benefits from EGFR-TKIs. Morevoer, progression of cancer is inevitable even though the standard treatment is given, while second-line treatments such as pemetrexed, docetaxel and EGFR-TKIs, which result in equivalent benefits have a response rate below 10% [6, 10]. It remains an Rabbit polyclonal to ITM2C important issue whether EGFR-TKIs and cytotoxic chemotherapy in combination can bring more benefits. Unfortunately, 4 large, randomized phase III clinical trials (INTACT-1, INTACT-2, TALENT and TRIBUTE) of administration of erlotinib or gefitinib in combination with standard first-line chemotherapy have failed to improve survival in patients with advanced NSCLC [11C14]. The failures to achieve the expected positive results could owe to the lack of predictive markers of response to EGFR-TKIs in combination with chemotherapy, or the sequence dependency of the antiproliferative effects of the combination therapies. Therefore, more preclinical experiments are needed to elucidate the mechanism of chemotherapies used in combiantion with EGFR-TKIs in tumor cells to guide rational use of combination therapies in clinical practice. Pemetrexed is a novel antifolate, which inhibits dihydrofolate reductase through blocking three important metabolic enzymes involved in DNA PE859 synthesis: dihydrofolate reductasem (DHFR), glycinamide ribonucleotide formyltransferase, and the most important target-thymidylate synthase [15]. As a first-line therapy for advanced NSCLC, pemetrexed alone has yielded an overall survival (OS) of 4.7?months, and a median progression-free survival (PFS) of 3.3?months [16]. Pemetrexed-based chemotherapy (PBC) has yielded an average OS of 10.3?months [17]. As a single agent in second-line treatment for advanced NSCLC, pemetrexed has yielded a median survival time of 8.3?months and a median PFS of 2.9?months. Also, for maintenance therapy of NSCLC, pemetrexed significantly improved PFS from 2.6?months to 4.3?months [18]. Because of the exact curative effect, pemetrexed was approved for NSCLC in 2008 by Food and Drug Administration (FDA). Icotinib hydrochloride, similar to gefitinib and erlotinib, is a potent EGFR-TKI. In vitro preclinical studies reported that icotinib selectively inhibited the EGFR members including both wild-type and mutants with inhibition efficacies of 61C99%, without affecting the other 81 kinds of kinases [19, 20]. The phase III trial (ICOGEN) with a randomized, double-blind, multicenter, controlled, head-to-head.Firstly, PC-9 cells were treated with increasing exposure time to pemetrexed with the concentration of 0.4?M. and transwell invasion assays respectively; protein expression was by detected by Western blot. Results The growth inhibition effect of pemetrexed combined with icotinib on NSCLC cells were schedule-dependent in vitro in vivo. Treatment with pemetrexed followed by icotinib (P-I) had significantly stronger anticancer ability than treatment with icotinib followed by pemetrexed (I-P) and concomitant treatment with pemetrexed and icotinib (P?+?I). Cell cycle analysis revealed that pemetrexed blocked cells in S phase, whereas icotinib arrested cells in G1 phase. We also found that icotinib markedly enhanced the pro-apoptotic activity of pemetrexed via cytochrome-C/Caspase/Bcl-2 signaling pathway. In addition, our results showed that pemetrexed alone increased the levels of p-EGFR, p-AKT and p-MAPK, which were inhibited by icotinib. Finally, we showed that the washout period of icotinib was no less than 96?h. Conclusions Sequential treatment of NSCLC cells with pemetrexed followed by icotinib had powerful antiproliferative effect, and it could become a novel effective combination therapy for NSCLC patients. strong class=”kwd-title” Keywords: Icotinib, Lung cancer, EGFR mutation, Synergy, Washout period Background Primary lung cancer is the most common form of cancer in terms of both incidence and death worldwide [1]. Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer and accounts for about 80% of all lung cancer [2], The overall 5-year survival rate for stage IIIB/IV NSCLC is 1C5%, and approximately 70% of NSCLC patients are diagnosed at an advanced stage with local metastasis [3]. Systemic therapy is the backbone of treatments of advanced NSCLC. First-line platinum-based doublet chemotherapy or teratment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) is optional according to EGFR status [4C9]. However, the benefits of first-line chemotherapy seem to have reached a plateau and only progress free survival (PFS) benefits from EGFR-TKIs. Morevoer, progression of cancer is inevitable even though the standard treatment is given, while second-line treatments such as pemetrexed, docetaxel and EGFR-TKIs, which result in equivalent benefits have a response rate below 10% [6, 10]. It remains an important issue whether EGFR-TKIs and cytotoxic chemotherapy in combination can bring more benefits. Unfortunately, 4 large, randomized phase III clinical trials (INTACT-1, INTACT-2, TALENT and TRIBUTE) of administration of erlotinib or PE859 gefitinib in combination with standard first-line chemotherapy have failed to improve survival in individuals with advanced NSCLC [11C14]. The failures to achieve the expected positive results could owe to the lack of predictive markers of response to EGFR-TKIs in combination with chemotherapy, or the sequence dependency of the antiproliferative effects of the combination therapies. Therefore, more preclinical experiments are needed to elucidate the mechanism of chemotherapies used in combiantion with EGFR-TKIs in tumor cells to guide rational use of combination therapies in medical practice. Pemetrexed is definitely a PE859 novel antifolate, which inhibits dihydrofolate reductase through obstructing three important metabolic enzymes involved in DNA synthesis: dihydrofolate reductasem (DHFR), glycinamide ribonucleotide formyltransferase, and the most important target-thymidylate synthase [15]. Like a first-line therapy for advanced NSCLC, pemetrexed only has yielded an overall survival (OS) of 4.7?weeks, and a median progression-free survival (PFS) of 3.3?weeks [16]. Pemetrexed-based chemotherapy (PBC) offers yielded an average OS of 10.3?weeks [17]. As a single agent in second-line treatment for advanced NSCLC, pemetrexed offers yielded a median survival time of 8.3?weeks and a median PFS of 2.9?weeks. Also, for maintenance therapy of NSCLC, pemetrexed significantly improved PFS from 2.6?weeks to 4.3?weeks [18]. Because of the exact curative effect, pemetrexed was authorized for NSCLC in 2008 by Food and Drug Administration (FDA). Icotinib hydrochloride, much like gefitinib and erlotinib, is definitely a potent EGFR-TKI. In vitro preclinical studies reported that icotinib selectively inhibited the EGFR users including both wild-type and mutants with inhibition efficacies of 61C99%, without influencing the additional 81 kinds of kinases [19, 20]. The phase III trial (ICOGEN) having a randomized, double-blind, multicenter, controlled, head-to-head study design indicated the efficacy differences were not significant between the icotinib-treated group.